In part 1 we looked at the authors and introduction of Once-weekly semaglutide 72 mg in adults with ob*sity (STEP UP): a randomised, controlled, phase 3b trial. Summary The trial over-represented cis women (who have been found to have greater weight loss on GLP-1s) and underrepresented People of Color with no trans or non-binary representation
This means that semaglutide (marketed as Wegovy) will soon be licensed and will no longer need to be prescribed off-label
The dosage may vary based on individual factors, such as the severity of the condition and response to treatment
Instead of recalling workers at peak times and laying them off when production demand fell, Lilly's regular workforce produced less-costly medicines in off-peak times using the same manufacturing facilities
NICE have set the following criteria for use of liraglutide in obesity: AND AND Prescription must be via a tier 3 weight management service (to ensure appropriate diet, lifestyle, and psychological supportplus the NHS gets a discount when prescribed through this route!) What does this mean for John